0.00
price down icon100.00%   -0.0941
after-market After Hours: .09 0.09 +
loading
Palatin Technologies Inc. stock is traded at $0.00, with a volume of 0. It is down -100.00% in the last 24 hours and down -100.00% over the past month. Palatin Technologies, Inc., a biopharmaceutical company, develops targeted, receptor-specific therapeutics for the treatment of various diseases in the United States. The company's principal product is Vyleesi, an on demand subcutaneous injectable product that has completed Phase III clinical studies for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. Its drug development programs also include melanocortin receptor system program, such as PL-8177, a selective melanocortin receptor 1 agonist peptide for inflammatory bowel diseases; and PL-8331, a preclinical development candidate for treating ocular inflammation, as well as melanocortin receptor 4 peptides and orally-active small molecules to treat genetic metabolic and obesity disorders. In addition, the company develops natriuretic peptide receptor systems comprising PL­3994, a natriuretic peptide receptor-A agonist, which has completed Phase I clinical study for the treatment of cardiovascular indications; and PL-5028, a dual natriuretic peptide receptor A and C agonist that is in preclinical development for cardiovascular diseases, such as reducing cardiac hypertrophy and fibrosis. Palatin Technologies, Inc. was founded in 1986 and is based in Cranbury, New Jersey.
See More
Previous Close:
$0.0941
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$5.67M
Revenue:
$7.10M
Net Income/Loss:
$-31.59M
P/E Ratio:
0.00
EPS:
-2.61
Net Cash Flow:
$-26.75M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
Value
$0.00
$0.00
1-Week Range:
Value
$0.00
$0.00
52-Week Range:
Value
$0.00
$2.0944

Palatin Technologies Inc. Stock (PTN) Company Profile

Name
Name
Palatin Technologies Inc.
Name
Phone
609-495-2200
Name
Address
Cedar Brook Corporate Center, 4B Cedar Brook Drive, Cranbury, NJ
Name
Employee
19
Name
Twitter
@PalatinTech
Name
Next Earnings Date
2024-11-12
Name
Latest SEC Filings
Name
PTN's Discussions on Twitter

Compare PTN with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
PTN
Palatin Technologies Inc.
0.00 5.67M 7.10M -31.59M -26.75M -2.61
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
450.91 114.57B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
522.68 55.88B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
308.78 39.64B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
551.22 35.64B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
264.42 28.55B 3.81B -644.79M -669.77M -6.24

Palatin Technologies Inc. Stock (PTN) Upgrades & Downgrades

Date Action Analyst Rating Change
Jun-05-15 Reiterated Canaccord Genuity Buy
Jan-12-15 Reiterated ROTH Capital Buy
May-23-12 Initiated Noble Financial Buy
Jan-23-07 Initiated Next Generation Buy

Palatin Technologies Inc. Stock (PTN) Latest News

pulisher
Jun 13, 2025

Palatin Technologies Raises $340K in Private Placement - TipRanks

Jun 13, 2025
pulisher
May 27, 2025

Palatin Technologies (PALI) Teams Up with Key Managers for Inves - GuruFocus

May 27, 2025
pulisher
May 27, 2025

Palatin Technologies (PALI) Teams Up with Key Managers for Investment Strategy | PALI Stock News - GuruFocus

May 27, 2025
pulisher
May 25, 2025

Palatin Technologies, Inc. (AMEX:PTN) Q3 2025 Earnings Call Transcript - MSN

May 25, 2025
pulisher
May 20, 2025

Palatin Technologies (NYSE:PTN) Coverage Initiated by Analysts at StockNews.com - Defense World

May 20, 2025
pulisher
May 15, 2025

Moderate Dry Eye Market Growth to Accelerate in Forecast Period (2023-2032), DelveInsight Analyzes | mc2 therapeutics, Palatin Technologies, Novaliq - The Globe and Mail

May 15, 2025
pulisher
May 15, 2025

Palatin Reports Fiscal Year 2025 Third Quarter Results and Business Update - The Malaysian Reserve

May 15, 2025
pulisher
May 15, 2025

Palatin Technologies Inc (PTNT) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance

May 15, 2025
pulisher
May 15, 2025

Palatin Technologies Inc (PTNT) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - GuruFocus

May 15, 2025
pulisher
May 14, 2025

Earnings call transcript: Palatin’s Q3 FY2025 shows narrower loss By Investing.com - Investing.com Nigeria

May 14, 2025
pulisher
May 14, 2025

Earnings call transcript: Palatin’s Q3 FY2025 shows narrower loss - Investing.com Australia

May 14, 2025
pulisher
May 14, 2025

Palatin Technologies Q1 Net Loss Narrows On Lower Expenses - Nasdaq

May 14, 2025
pulisher
May 14, 2025

Palatin Technologies (PTN) to Release Quarterly Earnings on Wednesday - Defense World

May 14, 2025
pulisher
May 12, 2025

Palatin Technologies director Robert DeVeer buys $10,180 in stock By Investing.com - Investing.com Nigeria

May 12, 2025
pulisher
May 12, 2025

Palatin Technologies director Robert DeVeer buys $10,180 in stock - Investing.com

May 12, 2025
pulisher
May 10, 2025

Palatin reveals potential diabetic retinopathy treatments - Investing.com

May 10, 2025
pulisher
May 10, 2025

Palatin reveals potential diabetic retinopathy treatments By Investing.com - Investing.com India

May 10, 2025
pulisher
May 09, 2025

Palatin Unveils Promising Preclinical Data For Diabetic Retinopathy Treatments At ARVO 2025 - Nasdaq

May 09, 2025
pulisher
May 09, 2025

Palatin Technologies Announces Closing of Reduced Public Offerin - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Two new option listings and two option delistings on May 9th - TipRanks

May 09, 2025
pulisher
May 09, 2025

Palatin Presents Promising Preclinical Data on Melanocortin Agonists for Retinopathy at ARVO 2025 - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Palatin expects $11.5M financing to cure NYSE American delisting notice - MSN

May 09, 2025
pulisher
May 09, 2025

Palatin Technologies Announces Closing of Reduced Public Offering - Financial Times

May 09, 2025
pulisher
May 08, 2025

Palatin Technologies Announces Closing of Reduced Public Offering | PTN Stock News - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Palatin Presents Breakthrough Symptom Resolution Data from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease at ARVO 2025 - The Malaysian Reserve

May 08, 2025
pulisher
May 08, 2025

Palatin Technologies (PTN) Reveals Promising Phase 3 Study Results for PL9643 in Dry Eye Disease | PTN Stock News - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Palatin Presents Breakthrough Symptom Resolution Data from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease at ARVO 2025 | PTN Stock News - GuruFocus

May 08, 2025
pulisher
May 08, 2025

PTN Faces Delisting from NYSE American, Shares Transition to OTC Market | PTN Stock News - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Palatin Technologies Announces Transition to OTC Pink Following NYSE American Delisting Notice - Lelezard

May 08, 2025
pulisher
May 07, 2025

Palatin Technologies Announces Transition to OTC Pink Following NYSE American Delisting Notice | PTN Stock News - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Palatin Technologies faces delisting from NYSE American due to low stock price - Investing.com Nigeria

May 07, 2025
pulisher
May 07, 2025

NYSE American to Commence Delisting Proceedings Against Palatin Technologies, Inc. (PTN) - Business Wire

May 07, 2025
pulisher
May 07, 2025

Palatin secures $11.5 million to tackle NYSE delisting, boost obesity drugs - Investing.com Australia

May 07, 2025
pulisher
May 07, 2025

Palatin Technologies sets terms for $23 million offering By Investing.com - Investing.com South Africa

May 07, 2025
pulisher
May 07, 2025

Palatin secures $11.5 million to tackle NYSE delisting, boost obesity drugs By Investing.com - Investing.com South Africa

May 07, 2025
pulisher
May 07, 2025

Palatin Prices $11.5 Mln Public Offering - Nasdaq

May 07, 2025
pulisher
May 07, 2025

Palatin Expects $11.5 Mln Offering To Aid NYSE Compliance And Fuel Obesity Drug Development - Nasdaq

May 07, 2025
pulisher
May 07, 2025

Palatin (PTN) Aims to Address Delisting Concerns with Public Off - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Palatin Technologies Stock Trading Halted Pending Material Announcement - marketscreener.com

May 07, 2025
pulisher
May 07, 2025

Palatin Expects $11.5 Million Financing to Cure NYSE American De - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Palatin Expects $11.5 Million Financing - citybiz

May 07, 2025
pulisher
May 07, 2025

Palatin Technologies Announces Pricing Of Up To $23 Million Public Offering - marketscreener.com

May 07, 2025
pulisher
May 07, 2025

Palatin Technologies Announces Pricing of up to $23 Million Public Offering - GuruFocus

May 07, 2025

Palatin Technologies Inc. Stock (PTN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$71.22
price up icon 5.12%
$22.86
price up icon 0.18%
$35.10
price up icon 0.75%
$19.95
price up icon 0.86%
$106.33
price down icon 0.23%
biotechnology ONC
$264.42
price down icon 1.93%
Cap:     |  Volume (24h):